Information Provided By:
Fly News Breaks for January 26, 2018
RDHL
Jan 26, 2018 | 09:30 EDT
Nomura Instinet analyst Chris Marai started RedHill Biopharma with a Buy rating and $18 price target. The analyst views the risk/reward as attractive ahead of catalysts in 2018.
News For RDHL From the Last 2 Days
There are no results for your query RDHL